Literature DB >> 10414702

The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability.

S Kobayashi1, Y Koide, M Endo, K Isono, T Ochiai.   

Abstract

BACKGROUND: The p53 gene alteration is identified in approximately half of all human tumors, and is now thought to be a key gene for regulating the cell cycle through the induction of p21(WAF1/CIP1) and inducing apoptosis through some genes such as BAX. In this study, we investigated the prognostic value of p53 mutation for postoperative esophageal squamous cell carcinoma patients.
METHODS: The subjects studied were 42 esophageal squamous cell carcinoma patients who underwent esophagectomy with complete curability in our department. The cases were limited to stage II and III. DNA was extracted from paraffin-embedded tissues. A p53 gene mutation was detected by polymerase chain reaction-single strand conformation polymorphism and subsequent direct sequencing method for exons 5 to 9. The 5-year survival rate was calculated and statistically compared between the p53 mutation(+) and (-) groups by the log rank test.
RESULTS: The p53 gene mutation was identified in 14 cases (33.3%). The 5-year survival rate of the p53 mutation(-) group (n = 28) was significantly higher than the (+) group (n = 14; 51.0% versus 35.7%, P <0.05 by the log rank test). Recurrence could be identified in 10 of 14 p53 mutation(+) cases (71.4%), whereas it was found in 12 of 28 (-) cases (42.8%).
CONCLUSION: The current study indicated that p53 mutation of tumor tissues might be a prognostic factor for esophageal squamous cell carcinoma cases and one of the risk factors for its recurrence.

Entities:  

Mesh:

Year:  1999        PMID: 10414702     DOI: 10.1016/s0002-9610(99)00085-9

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  7 in total

Review 1.  Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Authors:  Hiroshi Saeki; Yuichiro Nakashima; Yoko Zaitsu; Yasuo Tsuda; Yuta Kasagi; Koji Ando; Yu Imamura; Kippei Ohgaki; Shuhei Ito; Yasue Kimura; Akinori Egashira; Eiji Oki; Masaru Morita; Yoshihiko Maehara
Journal:  Surg Today       Date:  2015-03-05       Impact factor: 2.549

2.  Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus.

Authors:  Ines Gockel; Kathrin Dirksen; Claudia-M Messow; Theodor Junginger
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

Review 3.  p53 gene therapy for esophageal cancer.

Authors:  Hideaki Shimada; Hisahiro Matsubara; Takenori Ochiai
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

4.  p53 expression in squamous dysplasia associated with carcinoma of the oesophagus: evidence for field carcinogenesis.

Authors:  M Yasuda; H Kuwano; M Watanabe; Y Toh; S Ohno; K Sugimachi
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

5.  Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma.

Authors:  H Shimada; T Hoshino; S Okazumi; H Matsubara; Y Funami; Y Nabeya; H Hayashi; A Takeda; T Shiratori; T Uno; H Ito; T Ochiai
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

6.  PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.

Authors:  Haruna Furukawa; Tomoki Makino; Makoto Yamasaki; Koji Tanaka; Yasuhiro Miyazaki; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Cancer Sci       Date:  2017-12-28       Impact factor: 6.716

Review 7.  A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.

Authors:  J M Findlay; M R Middleton; I Tomlinson
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.